Vilket är priset för Abivax S.A. (ABVX)

Priset för Abivax S.A. (ABVX) är $121.34

Vilket är marknadsvärdet för Abivax S.A. (ABVX)

Marknadsvärdet för Abivax S.A. (ABVX) är $10.58B

Abivax S.A. (ABVX) Vinst per Aktie

Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.

År	EPS	Ändra
Inte tillräckligt med data för de angivna datumen.

År

EPS

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	EPS	EPS-differens	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Moderna, Inc. MRNA.US	$-7.98	-	US
CSL Limited CSL.AX	$-5.29	-	AU
Lonza Group AG LONN.SW	-	-	CH

Företag

EPS

EPS-differens

Land

Vertex Pharmaceuticals Incorporated

VRTX.US

$17.32

Argenx SE

ARGX.US

$27.74

Moderna, Inc.

MRNA.US

$-7.98

CSL Limited

CSL.AX

$-5.29

Lonza Group AG

LONN.SW

Abivax S.A.

ABVX

Kategori